163 related articles for article (PubMed ID: 37974211)
1. Proton therapy (PT) combined with concurrent chemotherapy for locally advanced non-small cell lung cancer with negative driver genes.
Jin Y; Shimizu S; Li Y; Yao Y; Liu X; Si H; Sakurai H; Xiao W
Radiat Oncol; 2023 Nov; 18(1):189. PubMed ID: 37974211
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
3. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
4. [Proton beam therapy with concurrent chemotherapy for non-small cell lung cancer -- our experiences and future direction].
Niho S; Motegi A; Akimoto T
Gan To Kagaku Ryoho; 2015 Feb; 42(2):144-7. PubMed ID: 25743132
[TBL] [Abstract][Full Text] [Related]
5. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
[TBL] [Abstract][Full Text] [Related]
6. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis.
Makishima H; Ishikawa H; Terunuma T; Hashimoto T; Yamanashi K; Sekiguchi T; Mizumoto M; Okumura T; Sakae T; Sakurai H
J Radiat Res; 2015 May; 56(3):568-76. PubMed ID: 25755255
[TBL] [Abstract][Full Text] [Related]
7. [The efficacy of radiotherapy based combined therapy for unresectable locally invasive bladder cancer and its associated factors analysis].
Zhong SJ; Gao JJ; Tang P; Liu YP; Wang SL; Fang H; Qiu JP; Song YW; Chen B; Qi SN; Tang Y; Lu NN; Jing H; Zhai YR; Zhou AP; Bi XG; Ma JH; Li CL; Zhang Y; Shou JZ; Xing NZ; Li YX
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):175-181. PubMed ID: 36781240
[No Abstract] [Full Text] [Related]
8. Sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: our experience.
Crvenkova S; Krstevska V
Prilozi; 2009 Dec; 30(2):197-207. PubMed ID: 20087260
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis.
Chen Y; Luo H; Liu R; Tan M; Wang Q; Wu X; Du T; Liu Z; Sun S; Zhang Q; Wang X
Radiat Oncol; 2023 May; 18(1):86. PubMed ID: 37217970
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis.
Zhao L; Zhao Z; Yan X; Wu F; Sun N; Guo R; Yu S; Hu X; Feng J
Int J Clin Pract; 2024; 2024():8585035. PubMed ID: 38375028
[TBL] [Abstract][Full Text] [Related]
11. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer.
Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS
Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357
[TBL] [Abstract][Full Text] [Related]
14. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007.
Takigawa N; Kiura K; Segawa Y; Hotta K; Tamaoki A; Tokuda Y; Nagata T; Watanabe K; Gemba K; Moritaka T; Horita N; Takeda H; Okimoto N; Takemoto M; Matsuo K; Shinkai T; Tabata M; Ueoka H; Kanazawa S; Tanimoto M
J Thorac Oncol; 2011 Jun; 6(6):1087-91. PubMed ID: 21415777
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy.
Zhang Z; Xu J; Zhou T; Yi Y; Li H; Sun H; Huang W; Wang D; Li B; Ying G
Radiat Oncol; 2014 Feb; 9():54. PubMed ID: 24528546
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.
Nguyen QN; Ly NB; Komaki R; Levy LB; Gomez DR; Chang JY; Allen PK; Mehran RJ; Lu C; Gillin M; Liao Z; Cox JD
Radiother Oncol; 2015 Jun; 115(3):367-72. PubMed ID: 26028228
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
18. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
[TBL] [Abstract][Full Text] [Related]
19. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
20. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery.
Patel AB; Edelman MJ; Kwok Y; Krasna MJ; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1106-12. PubMed ID: 15519781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
